Evidence map›Paper›PMID 35008201›Full record

ArticleCancers2021

Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.

Mathias Dahlmann, Anne Monks, Erik D Harris, Dennis Kobelt, Marc Osterland, Fadi Khaireddine, Pia Herrmann, Wolfgang Kemmner, Susen Burock, Wolfgang Walther and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Methyltransferase-like 3/14-mediated mResearch (Washington, D.C.) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Biological factors driving colorectal cancer metastasis.World journal of gastrointestinal oncology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. The mFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Mathias DahlmannExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.ORCID 0000-0002-0036-5283
Anne MonksMolecular Pharmacology Laboratory, Leidos Biomedical Research, Inc., FNLCR, Frederick, MD 21702, USA.
Erik D HarrisMolecular Pharmacology Laboratory, Leidos Biomedical Research, Inc., FNLCR, Frederick, MD 21702, USA.
Dennis KobeltExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.
Marc OsterlandExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.ORCID 0000-0001-9133-9322
Fadi KhaireddineExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.
Pia HerrmannExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.
Wolfgang KemmnerExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.
Susen BurockCharité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Invalidenstraße 80, 10117 Berlin, Germany.
Wolfgang WaltherExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.
Robert H ShoemakerScreening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Building 440, Frederick, MD 21702, USA.
Ulrike SteinExperimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.ORCID 0000-0001-7006-282X
Max Delbrück Center · DELeidos (United States) · USFrederick National Laboratory for Cancer Research · USGerman Cancer Research Center · DEHumboldt-Universität zu Berlin · DE

Funding

Deutsche Forschungsgemeinschaft STE 671/8 1NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Metastasis is directly linked to colorectal cancer (CRC) patient survival. Wnt signaling through β-catenin plays a key role. Metastasis-inducing S100A4 is a Wnt/β-catenin target gene and a prognostic biomarker for CRC and other cancer types. We aimed to identify S100A4-dependent expression alterations to better understand CRC progression and metastasis for improved patient survival. S100A4-induced transcriptome arrays, confirmatory studies in isogenic CRC cell lines with defined β-catenin genotypes, and functional metastasis studies were performed. S100A4-regulated transcriptome examination revealed the transcriptional cross-regulation of metastasis-inducing S100A4 with Wnt pathway antagonist Dickkopf-1 (DKK1). S100A4 overexpression down-regulated DKK1, S100A4 knock-down increased DKK1. Recombinant DKK1 reduced S100A4 expression and S100A4-mediated cell migration. In xenografted mice, systemic S100A4-shRNA application increased intratumoral DKK1. The inverse correlation of S100A4 and DKK1 was confirmed in five independent publicly available CRC expression datasets. Combinatorial analysis of S100A4 and DKK1 in two additional independent CRC patient cohorts improved prognosis of overall and metastasis-free survival. The newly discovered transcriptional cross-regulation of Wnt target S100A4 and Wnt antagonist DKK1 is predominated by an S100A4-induced Wnt signaling feedback loop, increasing cell motility and metastasis risk. S100A4 and DKK1 combination improves the identification of CRC patients at high risk.

Indexed as

colorectal cancerDKK1patient survivalS100A4Wnt signaling

Identifiers

PMID35008201
PMCPMC8750436
OpenAlexW4200370949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.